CellSource Co., Ltd.
4880.T
Get informed when a big investor buys or sells
+ FollowMarket Cap$6.17B
Close$
Share Statistics
| Market cap | $6.17 Billion |
|---|---|
| Enterprise Value | $1.46 Billion |
| Dividend Yield | $5.00 (1.61%) |
| Earnings per Share | $0.54 |
| Beta | -0.09 |
| Outstanding Shares | 19,850,799 |
Return
| Return on Equity | 1.63% |
|---|---|
| Return on Assets | 1.42% |
| Return on Invested Capital | 3.40% |
Valuation & Multiples
| P/E Ratio | 62.58 |
|---|---|
| PEG | 166.71 |
| Price to Sales | 1.8 |
| Price to Book Ratio | 1.02 |
| Enterprise Value to Revenue | 0.42 |
| Enterprise Value to EBIT | 6.57 |
| Enterprise Value to Net Income | 14 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
September 8, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$896.00 M
Average shareholder expectationNext Earnings Call
Expected Date
December 10, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$814.00 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About CellSource Co., Ltd.
148 employees
CEO: Masayuki Yamakawa CellSource Co., Ltd. operates within both the regenerative medicine and consumer product sectors. Among its offerings is Signalift, an anti-aging solution. The company, which was established in 2015, is headquartered in Tokyo, Japan.